Active Ingredient History
Quinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. It is a stereoisomer of quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. Like all other class I antiarrhythmic agents, quinidine primarily works by blocking the fast inward sodium current (INa). Quinidine's effect on INa is known as a 'use-dependent block'. This means at higher heart rates, the block increases, while at lower heart rates, the block decreases. The effect of blocking the fast inward sodium current causes the phase 0 depolarization of the cardiac action potential to decrease (decreased Vmax). Quinidine also blocks the slowly inactivating, tetrodotoxin-sensitive Na current, the slow inward calcium current (ICA), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito. Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6 and can lead to increased blood levels of lidocaine, beta blockers, opioids, and some antidepressants. Quinidine also inhibits the transport protein P-glycoprotein and so can cause some peripherally acting drugs such as loperamide to have central nervous system side effects, such as respiratory depression if the two drugs are coadministered. Quinidine can cause thrombocytopenia, granulomatous hepatitis, myasthenia gravis, and torsades de pointes, so is not used much today. Torsades can occur after the first dose. Quinidine-induced thrombocytopenia (low platelet count) is mediated by the immune system and may lead to thrombocytic purpura. A combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. This drug is marketed as Nuedexta in the United States. Intravenous quinidine is also indicated for the treatment of Plasmodium falciparum malaria. However, quinidine is not considered the first-line therapy for P. falciparum. The recommended treatments for P. falciparum malaria, according to the Toronto Notes 2008, are a combination of either quinine and doxycycline or atovaquone and proguanil (Malarone). The drug is also effective for the treatment of atrial fibrillation in horses. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arrhythmias, Cardiac (approved 1950)
Atrial Fibrillation (approved 1950)
Malaria, Falciparum (approved 1950)
Alzheimer Disease (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 3)
Anxiety (Phase 2)
Arrhythmias, Cardiac (Phase 3)
Atrial Fibrillation (Phase 4)
Autistic Disorder (Phase 2)
Brain Injuries, Traumatic (Phase 4)
Cardiovascular Diseases (Phase 3)
Constipation (Phase 1)
COVID-19 (Phase 1)
Crying (Phase 4)
Death, Sudden, Cardiac (Phase 3)
Dementia (Phase 4)
Depressive Disorder, Major (Phase 2)
Dyskinesias (Phase 2)
Healthy Volunteers (Phase 1)
Heart Arrest (Phase 3)
Heart Diseases (Phase 3)
Hepatitis B (Phase 1)
Huntington Disease (Phase 3)
Irritable Mood (Phase 3)
Migraine Disorders (Phase 2)
Multiple Sclerosis (Phase 3)
Myocardial Infarction (Phase 3)
Non-alcoholic Fatty Liver Disease (Phase 1)
Pain (Phase 2)
Parkinson Disease (Phase 3)
Pharmacology (Phase 1)
Pseudobulbar Palsy (Phase 4)
Respiratory Syncytial Virus Infections (Phase 1)
Stroke (Phase 4)
Tachycardia, Ventricular (Phase 3)
Ventricular Fibrillation (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
